CA2452606C - Tetrahydroquinoline derivatives - Google Patents

Tetrahydroquinoline derivatives Download PDF

Info

Publication number
CA2452606C
CA2452606C CA2452606A CA2452606A CA2452606C CA 2452606 C CA2452606 C CA 2452606C CA 2452606 A CA2452606 A CA 2452606A CA 2452606 A CA2452606 A CA 2452606A CA 2452606 C CA2452606 C CA 2452606C
Authority
CA
Canada
Prior art keywords
alkyl
phenyl
acetyl
tetrahydro
amino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA2452606A
Other languages
English (en)
French (fr)
Other versions
CA2452606A1 (en
Inventor
Nicole Corine Renee Van Straten
Rudolf Gijsbertus Van Someren
Jurgen Schulz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp & Dohme BV
Original Assignee
Organon NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Organon NV filed Critical Organon NV
Publication of CA2452606A1 publication Critical patent/CA2452606A1/en
Application granted granted Critical
Publication of CA2452606C publication Critical patent/CA2452606C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/16—Masculine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A61P5/08—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH for decreasing, blocking or antagonising the activity of the anterior pituitary hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/04—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to the ring carbon atoms
    • C07D215/08—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to the ring carbon atoms with acylated ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Epidemiology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Quinoline Compounds (AREA)
CA2452606A 2001-07-02 2002-06-25 Tetrahydroquinoline derivatives Expired - Fee Related CA2452606C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP01202531.8 2001-07-02
EP01202531 2001-07-02
PCT/EP2002/007053 WO2003004028A1 (en) 2001-07-02 2002-06-25 Tetrahydroquinoline derivatives

Publications (2)

Publication Number Publication Date
CA2452606A1 CA2452606A1 (en) 2003-01-16
CA2452606C true CA2452606C (en) 2011-09-13

Family

ID=8180574

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2452606A Expired - Fee Related CA2452606C (en) 2001-07-02 2002-06-25 Tetrahydroquinoline derivatives

Country Status (31)

Country Link
US (2) US8058441B2 (enExample)
EP (1) EP1406628B1 (enExample)
JP (1) JP4523273B2 (enExample)
KR (1) KR100908468B1 (enExample)
CN (1) CN1261099C (enExample)
AR (1) AR034669A1 (enExample)
AT (1) ATE319451T1 (enExample)
AU (1) AU2002317848B2 (enExample)
BR (1) BR0210645A (enExample)
CA (1) CA2452606C (enExample)
CY (1) CY1106087T1 (enExample)
CZ (1) CZ20042A3 (enExample)
DE (1) DE60209734T2 (enExample)
DK (1) DK1406628T3 (enExample)
EC (1) ECSP034932A (enExample)
ES (1) ES2260458T3 (enExample)
HR (1) HRP20031080A2 (enExample)
HU (1) HUP0400390A2 (enExample)
IL (1) IL159288A0 (enExample)
IS (1) IS2418B (enExample)
MX (1) MXPA03011908A (enExample)
NO (1) NO325516B1 (enExample)
NZ (1) NZ530198A (enExample)
PE (1) PE20030273A1 (enExample)
PL (1) PL367638A1 (enExample)
PT (1) PT1406628E (enExample)
RU (1) RU2347570C2 (enExample)
SA (1) SA02230260B1 (enExample)
SK (1) SK286759B6 (enExample)
WO (1) WO2003004028A1 (enExample)
ZA (1) ZA200309921B (enExample)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2452606C (en) 2001-07-02 2011-09-13 Akzo Nobel N.V. Tetrahydroquinoline derivatives
ATE416168T1 (de) * 2002-02-15 2008-12-15 Glaxo Group Ltd Modulatoren des vanilloidrezeptors
FR2836620B1 (fr) * 2002-02-28 2004-04-16 Snecma Services Instrument de projection thermique
SE0200920D0 (sv) * 2002-03-25 2002-03-25 Astrazeneca Ab Novel compounds
TWI322012B (en) * 2002-12-20 2010-03-21 Organon Nv Tetrahydroquinoline derivatives
TWI306855B (en) * 2002-12-20 2009-03-01 Organon Nv Tetrahydroquinoline derivatives
SE0300480D0 (sv) * 2003-02-21 2003-02-21 Astrazeneca Ab Novel compounds
MXPA05012705A (es) * 2003-05-29 2006-02-08 Astrazeneca Ab Una composicion farmaceutica que comprende un antagonista del receptor p2x7 y un factor alfa de necrosis tumoral.
WO2004105797A1 (en) * 2003-05-29 2004-12-09 Astrazeneca Ab A pharmaceutical composition comprising a p2x7 antagonist and sulfasalazine
EP1644042A1 (en) * 2003-05-29 2006-04-12 AstraZeneca AB A pharmaceutical composition containing a p2x7 receptor antagonist and methotrexate
GB0312609D0 (en) * 2003-06-02 2003-07-09 Astrazeneca Ab Novel compounds
KR100554155B1 (ko) * 2003-06-09 2006-02-22 학교법인 포항공과대학교 금속/반도체 나노막대 이종구조를 이용한 전극 구조물 및그 제조 방법
SE0302139D0 (sv) * 2003-07-28 2003-07-28 Astrazeneca Ab Novel compounds
SE0302192D0 (sv) * 2003-08-08 2003-08-08 Astrazeneca Ab Novel compounds
SE0302488D0 (sv) * 2003-09-18 2003-09-18 Astrazeneca Ab New combination
SA05260265A (ar) * 2004-08-30 2005-12-03 استرازينيكا ايه بي مركبات جديدة
SE0402925D0 (sv) * 2004-11-30 2004-11-30 Astrazeneca Ab Novel Compounds
US7691848B2 (en) 2005-03-02 2010-04-06 Wyeth Pyrrolobenzodiazepine arylcarboxamides and derivatives thereof as follicle-stimulating hormone receptor antagonists
CN101171234B (zh) 2005-05-04 2011-11-16 欧加农股份有限公司 二氢吡啶衍生物
UA92007C2 (ru) 2005-05-04 2010-09-27 Н.В. Органон Производные 4-фенил-5-оксо-1,4,5,6,7,8-гексагидрохинолина для лечения бесплодности
UA92009C2 (ru) * 2005-05-04 2010-09-27 Н.В. Органон Производные 4-фенил-5-оксо-1,4,5,6,7,8-гексагидрохинолина для лечения бесплодия
UA92008C2 (en) * 2005-05-04 2010-09-27 Н.В. Органон 4-PHENYL-5-OXO-l,4,5,6,7,8-HEXAHYDROQUINOLINE DERIVATIVES AS MEDICAMENTS FOR THE TREATMENT OF INFERTILITY
EP1879898A2 (en) 2005-05-12 2008-01-23 Wyeth a Corporation of the State of Delaware Pyrrolobenzodiazepines and heterocyclic carboxamide derivatives as follicle stimulating hormone receptor (fsh-r) antagonists
CN101208342A (zh) 2005-06-09 2008-06-25 惠氏公司 作为促卵泡激素受体拮抗剂的吡咯并苯并二氮杂䓬吡啶羧酰胺和衍生物
EP1912970A2 (en) * 2005-08-10 2008-04-23 Bayer Schering Pharma Aktiengesellschaft Acyltryptophanols for fertility control
US20070060573A1 (en) * 2005-08-10 2007-03-15 Lars Wortmann Acyltryptophanols
WO2008071453A1 (en) * 2006-12-13 2008-06-19 Bayer Schering Pharma Aktiengesellschaft 1,2-diarylacetylene derivatives of acyltryptophanols
EP1932831A1 (en) * 2006-12-13 2008-06-18 Bayer Schering Pharma Aktiengesellschaft 1,2-Diarylacetylene Derivatives of Acyltryptophanols
TWI410422B (zh) 2007-01-15 2013-10-01 Mitsubishi Tanabe Pharma Corp 縮合四氫喹啉衍生物及其醫藥用途
TW200848021A (en) 2007-03-06 2008-12-16 Wyeth Corp Sulfonylated heterocycles useful for modulation of the progesterone receptor
RU2460727C2 (ru) * 2007-03-22 2012-09-10 Астразенека Аб Хинолиновые производные для лечения воспалительных заболеваний
TW200918058A (en) * 2007-08-31 2009-05-01 Organon Nv TSH receptor antagonizing tetrahydroquinoline compounds
PE20091036A1 (es) 2007-11-30 2009-08-15 Astrazeneca Ab Derivado de quinolina como antagonista del receptor p2x7
RU2359684C1 (ru) * 2008-01-23 2009-06-27 Закрытое акционерное общество "СКАЙ ЛТД" Способ лечения эндометриоза
TW200944523A (en) 2008-02-08 2009-11-01 Organon Nv (Dihydro)pyrrolo[2,1-a]isoquinolines
US20100061976A1 (en) * 2008-07-24 2010-03-11 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Method for treating or preventing osteoporosis by reducing follicle stimulating hormone to cyclic physiological levels in a mammalian subject
TWI461426B (zh) * 2009-05-27 2014-11-21 Merck Sharp & Dohme （二氫）咪唑並異〔５，１－ａ〕喹啉類
US8071587B2 (en) 2009-05-27 2011-12-06 N. V. Organon (Dihydro)imidazoiso[5,1-A]quinolines
TW201116531A (en) 2009-07-29 2011-05-16 Organon Nv Ring-annulated dihydropyrrolo[2,1-a]isoquinolines
US8431564B2 (en) 2009-07-29 2013-04-30 Merck Sharp & Dohme B.V. Ring-annulated dihydropyrrolo[2,1-α]isoquinolines
TW201116515A (en) 2009-07-31 2011-05-16 Organon Nv Dihydrobenzoindazoles
ES2553771T3 (es) * 2010-10-08 2015-12-11 Nivalis Therapeutics, Inc. Nuevos compuestos de quinolina sustituidos como inhibidores de la S-nitrosoglutatión reductasa
US8546427B2 (en) * 2010-10-20 2013-10-01 Hoffmann-La Roche Inc. Tetrahydroquinoline derivatives
WO2016018553A1 (en) * 2014-07-30 2016-02-04 Henkel IP & Holding GmbH Cure accelerators for anaerobic curable compositions
US12275729B2 (en) 2017-11-01 2025-04-15 Merck Sharp & Dohme Llc Substituted tetrahydroquinolin compounds as indoleamine 2,3-dioxygenase (IDO) inhibitors
CN119954701B (zh) * 2024-06-18 2026-06-16 青岛润农化工有限公司 一种丁醚脲的合成方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2686182A (en) 1950-12-07 1954-08-10 Basf Ag O-hydroxy-dihydro-quinoline carboxylic acids
DE19975054I2 (de) 1987-08-08 2000-04-13 Akzo Nobel Nv Kontrazeptives Implantat
AU717251B2 (en) * 1994-12-22 2000-03-23 Ligand Pharmaceuticals Incorporated Steroid receptor modulator compounds and methods
WO2000008015A2 (en) * 1998-08-07 2000-02-17 Applied Research Systems Ars Holding N.V. Fsh mimetics for the treatment of infertility
JP2000143636A (ja) * 1998-09-02 2000-05-26 Sumitomo Pharmaceut Co Ltd アミノ誘導体
US6200963B1 (en) * 1999-03-31 2001-03-13 American Home Products Corporation Aryl sulfonic acids as FSH antagonists
CA2452606C (en) 2001-07-02 2011-09-13 Akzo Nobel N.V. Tetrahydroquinoline derivatives
TWI306855B (en) 2002-12-20 2009-03-01 Organon Nv Tetrahydroquinoline derivatives
TWI322012B (en) 2002-12-20 2010-03-21 Organon Nv Tetrahydroquinoline derivatives

Also Published As

Publication number Publication date
US20040236109A1 (en) 2004-11-25
ECSP034932A (es) 2004-02-26
HRP20031080A2 (en) 2004-04-30
RU2347570C2 (ru) 2009-02-27
EP1406628B1 (en) 2006-03-08
ATE319451T1 (de) 2006-03-15
DE60209734T2 (de) 2006-08-31
AR034669A1 (es) 2004-03-03
CY1106087T1 (el) 2011-06-08
JP2004535456A (ja) 2004-11-25
JP4523273B2 (ja) 2010-08-11
EP1406628A1 (en) 2004-04-14
ES2260458T3 (es) 2006-11-01
PT1406628E (pt) 2006-06-30
IS2418B (is) 2008-10-15
SK286759B6 (sk) 2009-05-07
IL159288A0 (en) 2004-06-01
KR100908468B1 (ko) 2009-07-21
AU2002317848B2 (en) 2006-08-31
DE60209734D1 (de) 2006-05-04
NZ530198A (en) 2005-11-25
US20120202996A1 (en) 2012-08-09
KR20040030714A (ko) 2004-04-09
CN1261099C (zh) 2006-06-28
US8058441B2 (en) 2011-11-15
PL367638A1 (en) 2005-03-07
DK1406628T3 (da) 2006-07-03
ZA200309921B (en) 2005-03-22
SA02230260B1 (ar) 2007-03-25
RU2004102693A (ru) 2005-06-27
MXPA03011908A (es) 2004-06-03
HUP0400390A2 (hu) 2004-09-28
CA2452606A1 (en) 2003-01-16
US8258293B2 (en) 2012-09-04
CZ20042A3 (en) 2004-04-14
HK1061810A1 (en) 2004-10-08
BR0210645A (pt) 2004-10-05
CN1529601A (zh) 2004-09-15
NO325516B1 (no) 2008-06-02
NO20035763L (no) 2003-12-29
IS7071A (is) 2003-12-11
PE20030273A1 (es) 2003-03-21
WO2003004028A1 (en) 2003-01-16
SK16342003A3 (sk) 2004-07-07

Similar Documents

Publication Publication Date Title
US8058441B2 (en) Tetrahydroquinoline derivatives
AU2002317848A1 (en) Tetrahydroquinoline derivatives
RU2328487C2 (ru) Производные тетрагидрохинолина, фармацевтическая композиция на их основе, их применение в качестве регуляторов фертильности
RU2328488C2 (ru) Производные тетрагидрохинолина, фармацевтическая композиция на их основе, их применение в качестве регуляторов фертильности
EP1879866A1 (en) Dihydropyridine derivatives
HK1061810B (en) Tetrahydroquinoline derivatives
TWI322144B (en) Tetrahydroquinoline derivatives
KR20050085694A (ko) 테트라히드로퀴놀린 유도체 및 ｆｓｈ 수용체조절인자로서의 이의 용도
HK1077576B (en) Tetrahydroquinoline derivatives and their use as fsh receptor modulators

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20190625